Predictive Ability of Serum IL-27 Level for Assessing Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Serum interleukin- (IL-) 27 level has been reported to increase in patients with several autoimmune diseases; however, its significance in patients with antineutrophil cytoplasmic antibody- (ANCA-) associated vasculitis (AAV) is unknown. In this study, we investigated the associations between serum IL-27, laboratory features, and activity of AAV and evaluate the predictive ability of serum IL-27 level for disease activity. This study included 77 AAV patients, and we collected clinical and laboratory data at blood sampling. Inflammation-related variables included white blood cell, neutrophil, lymphocyte and platelet counts, serum albumin, erythrocyte sedimentation rate, and C-reactive protein levels. Serum IL-27 and IL-18 levels were measured from stored sera using Human Magnetic Luminex® assay. High disease activity of AAV was defined as the highest tertile of Birmingham vasculitis activity score (BVAS) (≥11). The mean age of the enrolled patients was 59.9 years, and 38 (49.4%) were diagnosed as microscopic polyangiitis. In the multivariable analysis, serum albumin ( β = − 0.419 ) and serum IL-27 level ( β = 0.221 ) were significantly associated with BVAS. Furthermore, patients with renal manifestation exhibited higher serum IL-27 (mean 308.7 pg/mL vs. 105.8 pg/mL) and IL-18 levels (mean 376.7 pg/mL vs. 270.4 pg/mL) than those without. On applying the optimal cut-off of serum IL-27 level for predicting high activity, AAV patients with serum IL − 27 level ≥ 300.8 pg/mL had a significantly higher risk for having high disease activity than those with serum IL − 27 level < 300.8 pg/mL (relative risk 3.380, 95% confidence interval 1.223, 9.345, P = 0.016 ). These results suggest that serum IL-27 level is associated with the cross-sectional activity and the presence of renal manifestation and could be used to predict high disease activity in patients with AAV.

Download Full-text

Serum Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein-1 Can Predict Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Pilot Monocentric Study

BioMed Research International ◽

10.1155/2019/7508240 ◽

2019 ◽

Vol 2019 ◽

pp. 1-6 ◽

Cited By ~ 2

Author(s):

Sung Soo Ahn ◽

Jin-Ock Kim ◽

Taejun Yoon ◽

Jason Jungsik Song ◽

Yong-Beom Park ◽

...

Keyword(s):

Clinical Manifestations ◽

Multivariate Logistic Regression Analysis ◽

Antineutrophil Cytoplasmic Antibody ◽

Population Based ◽

Trna Synthetase ◽

Aminoacyl Trna Synthetase ◽

Serum Samples ◽

Cross Sectional ◽

Multifunctional Protein ◽

Protein Levels

We investigated whether serum aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) could predict severe cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) based on the Birmingham vasculitis activity score (BVAS). Sixty-one patients with AAV were selected for inclusion from our prospective AAV cohort. AAV-specific indices and clinical manifestations were assessed, and laboratory tests were performed on the day of blood sampling. Patients with severe AAV were defined as those with a BVAS higher than the lower limit of the highest tertile of BVAS (BVAS ≥ 12). We measured serum AIMP1 levels of the stored serum samples. A total of 20 (32.8%) and 41 (67.2%) patients were classified as having severe and nonsevere AAV according to the cut-off of BVAS ≥ 12. Patients with severe AAV showed higher frequencies of general and renal manifestations, along with ANCA positivity, and exhibited a higher mean neutrophil count, erythrocyte sedimentation rate, and C-reactive protein levels, but lower mean haemoglobin and serum albumin levels than those with nonsevere AAV. The mean serum AIMP1 level in patients with severe AAV was significantly higher than that of patients with nonsevere AIMP1 (351.1 vs. 98.4 pg/mL, p = 0.006). Multivariate logistic regression analysis including variables showing significance in univariate analyses revealed that only serum AIMP1 exhibited a significant association with severe AAV (odds ratio 1.004, p = 0.031). When we set the optimal cut-off of serum AIMP1 for severe AAV to 50.28 pg/mL, patients with severe AAV more frequently had AIMP1 levels above the cut-off than those with nonsevere AAV (80.0% vs. 31.7%, relative risk 8.615, p < 0.001). The results from our study suggest that serum AIMP1 can be used to estimate the cross-sectional severe AAV population based on the BVAS.

Download Full-text

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices

RMD Open ◽

10.1136/rmdopen-2020-001170 ◽

2020 ◽

Vol 6 (1) ◽

pp. e001170 ◽

Cited By ~ 1

Author(s):

Ennio Lubrano ◽

Silvia Scriffignano ◽

Ana Belen Azuaga ◽

Julio Ramirez ◽

Juan Canete ◽

...

Keyword(s):

Quality Of Life ◽

Psoriatic Arthritis ◽

Disease Activity ◽

Clinical Laboratory ◽

Laboratory Data ◽

Health Assessment ◽

Cross Sectional ◽

Low Disease Activity ◽

Patient Acceptable Symptom State

ObjectiveThe aim of this study was to evaluate the discriminant capability of the Patient Acceptable Symptom State (PASS) according to disease activity, remission/low disease activity indices and quality of life indices in patients with psoriatic arthritis (PsA).MethodsConsecutive patients with PsA were enrolled in this cross-sectional study. At each visit, the patients underwent a complete physical examination and their clinical/laboratory data were collected. Disease activity was assessed using the Disease Activity Score for Psoriatic Arthritis (DAPSA) and remission/low disease activity using the DAPSA minimal disease activity (MDA) and very low disease activity (VLDA) criteria. The Psoriatic Arthritis Impact of Disease (PsAID) and the Health Assessment Questionnaire-Disability Index scores were also collected. Finally, PASS was assessed by asking all patients to answer yes or no to a single question.ResultsPatients who answered yes to PASS showed a significantly better overall mean DAPSA score than those who were not in PASS. Furthermore, patients in PASS showed a significantly lower level of systemic inflammation, lower Leeds Enthesitis Index score, a significantly lower impact of disease (PsAID), lower pain and better function than patients who answered no to PASS. A moderate to good agreement was found between PASS, MDA, DAPSA low disease activity and PsAID score ≤4. Good sensitivity and specificity were found with PASS with respect to DAPSA low disease activity, and although PASS is sensitive in the identification of patients with MDA, DAPSA remission and VLDA it lacks of specificity.DiscussionThis study showed that PASS might be used as an alternative to determine disease activity in patients with PsA in real clinical practice, mainly in patients with low disease activity according to DAPSA criteria.

Download Full-text

Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity

Rheumatology ◽

10.1093/rheumatology/keaa590 ◽

2020 ◽

Author(s):

Laura de Armas-Rillo ◽

Juan C Quevedo-Abeledo ◽

Antonia de Vera-González ◽

Alejandra González-Delgado ◽

José A García-Dopico ◽

...

Keyword(s):

Disease Activity ◽

Lipid Profile ◽

Cholesterol Metabolism ◽

Multivariable Analysis ◽

Density Lipoprotein ◽

Intima Media Thickness ◽

Serum Levels ◽

Apolipoprotein A1 ◽

Proprotein Convertase ◽

Cross Sectional

Abstract Objective Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism and has been linked to cardiovascular (CV) risk. The purpose of the present study was to examine whether PCSK9 levels are related to abnormalities in the lipid profile and the development of atherosclerosis that occurs in patients with axial SpA (axSpA). Methods We performed a cross-sectional study that encompassed 545 individuals; 299 patients with axSpA and 246 statin use–matched controls. PCSK9 and standard lipid profiles were analysed in patients and controls. Carotid intima-media thickness (cIMT) and carotid plaques were assessed in patients. A multivariable analysis, adjusted for standard CV risk factors, was performed to evaluate the influence of PCSK9 on axSpA-related dyslipidaemia and subclinical carotid atherosclerosis. Results Total cholesterol, high-density lipoprotein and low density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein A1 were significantly lower in axSpA patients than controls. PCSK9 serum levels [β coefficient −44 ng/dl (95% CI −60, −27), P = 0.000] were also downregulated in axSpA patients after fully multivariable adjustment. ASDAS-CRP was found to be independently and significantly related to PCSK9 [β coefficient 10 ng/dl (95% CI 1, 18), P = 0.023] after analysing fully adjusted models that took age, sex and the rest of the lipid profile molecules into account. Whereas patients taking prednisone showed higher serum levels of PCSK9 [55 ng/ml (95% CI 24, 8), P = 0.001], those under anti-TNF-α therapies exhibited lower levels [β coefficient −26 ng/ml (95% CI −43, −9], P = 0.003]. Conclusion PCSK9 is downregulated in patients with axSpA. Disease activity is positive and significantly related to PSCK9. Anti-TNF-therapy yields a reduction in PCSK9 serum levels.

Download Full-text

Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers

Rheumatology ◽

10.1093/rheumatology/keaa167 ◽

2020 ◽

Vol 59 (11) ◽

pp. 3468-3478

Author(s):

François Chasset ◽

Camillo Ribi ◽

Marten Trendelenburg ◽

Uyen Huynh-Do ◽

Pascale Roux-Lombard ◽

...

Keyword(s):

Gene Expression ◽

Disease Activity ◽

Lupus Erythematosus ◽

High Disease Activity ◽

Polymorphonuclear Neutrophil ◽

Type I ◽

Individual Gene ◽

Protein Levels ◽

Highly Active ◽

I Gene

Abstract Objectives In SLE, heterogeneous clinical expression and activity may reflect diverse pathogenic and/or effector mechanisms. We investigated SLE heterogeneity by assessing the expression of three gene sets representative of type I IFN (IFN-I), polymorphonuclear neutrophil (PMN) and plasmablast (PB) signatures in a well-characterized, multidisciplinary cohort of SLE patients. We further assessed whether individual gene products could be representative of these three signatures. Methods Whole blood, serum and clinical data were obtained from 140 SLE individuals. Gene expression was assessed by NanoString technology, using a panel of 37 probes to compute six IFN-I, one PMN and one PB scores. Protein levels were measured by ELISA. Results Depending on the score, 45–50% of SLE individuals showed high IFN-I gene expression. All six IFN-I scores were significantly associated with active skin involvement, and two of six were associated with arthritis. IFN-induced Mx1 protein (MX1) level was correlated with IFN-I score (P < 0.0001) and associated with a similar clinical phenotype. In all, 25% of SLE individuals showed high PMN gene expression, associated with SLE fever, serositis, leukopoenia and glucocorticoid use. PB gene expression was highly affected by immunosuppressant agents, with no association with SLE features. Combined IFN-I and PMN gene scores were significantly associated with high disease activity and outperformed anti-dsDNA and anti-C1q autoantibody and complement levels for predicting SLE activity. Conclusion IFN-I and PMN gene scores segregate with distinct SLE clinical features, and their combination may identify high disease activity. MX1 protein level performed similar to IFN-I gene expression.

Download Full-text

AB0131 DIFFERENCES IN CLINICAL PARAMETERS AND LABORATORY DATA OF RHEUMATOID ARTHRITIS PATIENTS IN REMISSION OR WITH LOW DISEASE ACTIVITY TREATED WITH BIOLOGIC AGENTS OR JANUS KINASE INHIBITORS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.2771 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1094.1-1094

Author(s):

Y. Hirano ◽

J. Hasegawa ◽

H. Kosugiyama ◽

D. Kihira ◽

K. Hattori

Keyword(s):

Disease Activity ◽

Kinase Inhibitors ◽

Laboratory Data ◽

Biologic Agents ◽

Janus Kinase ◽

Clinical Parameters ◽

Cross Sectional ◽

Low Disease Activity ◽

Janus Kinase Inhibitors ◽

Cell Counts

Background:There are four kinds of drugs for rheumatoid arthritis (RA) patients who are refractory or intolerant to methotrexate (MTX) or other conventional synthetic disease-modifying anti-rheumatic drugs, namely, tumor necrosis factor inhibitors (TNFi), inteleukin-6 inhibitors (IL-6i), abatacept (ABT) and Janus kinase inhibitors (JAKi). Although these drugs have distinct mechanism of action (MOA) to reduce disease activity of RA, the effects of these drugs of reducing disease activity or inhibiting joint damage are similar according past clinical trials. However, their different MOA may induce different change in body of RA patients. If there are some differences in body of RA patients treated different drugs which have different MOA, some differences may appear in clinical parameters and laboratory data we clinician are able to know in daily clinical practice.Objectives:This retrospective cross-sectional study assessed differences in clinical parameters and laboratory data in RA patients who met the treatment goal with biologic agents (BIO) or JAKi.Methods:Data from the Toyohashi RA database (TRAD) was used. The TRAD is a collection of single-center retrospective data. Participants were BIO- or JAK-treated RA patients with clinical disease activity remission (REM) or low disease activity (LDA) [clinical disease activity index (CDAI) ≤ 10]categorized by BIO treatment with TNFi (reference), IL-6i, or ABT, and JAKi treatment. Clinical parameters [tender joint counts (TJ), swollen joint counts (SJ), patient’s global assessment (PtGA), patient’s pain assessment (PainVAS), physician’s global assessment (PhGA) and modified health assessment questionnaire (mHAQ)] and laboratory data [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), matrix metalloprotease-3 (MMP-3), white blood cell counts (WBC), hemoglobin (Hb), platelet cell counts (PLT), neutrophils counts (Neut), lymphocyte counts (Lymph) and estimated glomerular filtration rate (eGFR)] were investigated in cross-sectional manner. They are statistically compared using the Dunnett test.Results:171 TNFi, 71 IL-6i, 50 ABT, and 18 JAKi cases are categorized in REM or LDA. Patients’ characteristics (means) are as follows (TNFi/IL-6i/ABT/JAKi). Age (63.1/63.7/72.4/60.6; years old), RA duration (17.0/12.7/18.2/11.3; years), %female (83.0/71.8/88.0/83.3), %rheumatoid factor positive (81.9/80.3/90.0/88.9), %anti-cyclic citrullinated peptide antibody (84.6/74.6/97.9/73.3), %prednisolone (PSL) concomitant (3.5/4.2/18.0/11.1) and %MTX concomitant (77.2/15.5/26.0/83.3). Parameters with statistical significance (means) were: TNFi/IL-6i-ESR 34.5/14.0 mm/hr, MMP-3 47.5/71.9 ng/mL, WBC 6124/5404 /µL, Lymph 2112/1646 µL; TNFi/ABT-TJ 0.4/1.0, PtGA 13.3/20.0 mm, PainVAS 15.7/21.6 mm, PhGA 7.4/11.1 mm, CRP 0.1/0.4 mg/dL, ESR 34.5/44.2 mm/hr, MMP-3: 47.5/72.9 ng/mL, Lymph 2112/1816 µL, Neut 3364/4233 µL, eGFR 75.4/65.3 mL/min/1.73m2; and TNFi/JAKi-PLT 21.7/29.3 104/µL, Lymph 2112/1326 µL.Conclusion:Although differences of rates of administering concomitant PSL or MTX should be considered, clinical parameter and laboratory data differences result from differences in the targeted cytokine between TNFi and IL-6i, differences in patient characteristics between TNFi and ABT, and differences in the MOA between TNFi and JAKi.Disclosure of Interests:None declared

Download Full-text

Antineutrophil Cytoplasmic Antibody in Lupus Nephritis: Correlation with Clinicopathological Characteristics and Disease Activity

Current Rheumatology Reviews ◽

10.2174/1573397116999201208213422 ◽

2020 ◽

Vol 16 ◽

Author(s):

Dina Said ◽

Nearmeen Mohammed Rashad ◽

Nora Said Abdelrahmanc ◽

Ghada Aboelsaud Dawaa

Keyword(s):

Lupus Nephritis ◽

Disease Activity ◽

Lupus Erythematosus ◽

Activity Index ◽

Rapidly Progressive Glomerulonephritis ◽

Disease Activity Index ◽

Antineutrophil Cytoplasmic Antibody ◽

Systemic Lupus ◽

Cross Sectional ◽

Class Iv

Background:: Lupus nephritis (LN) represents 40%–50% of all systemic lupus erythematosus (SLE) patients, and rapidly progressive glomerulonephritis is associated with significant morbidity and mortality. Antineutrophil cytoplasmic antibody (ANCA) might be involved in the pathogenesis of LN. Objective:: We evaluated the role of myeloperoxidase (MPO)-ANCA, proteinase 3 (PR3)-ANCA, and anti-glomerular basement membrane autoantibodies (anti-GBM autoAb) for the diagnosis of LN. Methods:: In this cross-sectional study, 95 SLE patients were divided into 2 subgroups: LN group (n = 60) and non-LN group (n = 35). For further analysis, we subclassified the LN group into ANCA-positive (n = 16) and ANCA-negative (n = 44) LN patients. The entire Non-LN group was ANCA-negative. The SLE disease activity index (SLEDAI) was reported for each patient. Determination of MPO-ANCA, PR3-ANCA, and anti-GBM autoAb was performed using a novel multiplex bead-based technology in all patients. Data analyses were done using SPSS, version 20. Approval was obtained from the institutional review board of Zagazig University (ZU-IRB#6000). Results:: Of 95 patients with SLE, 16 patients (16.84%) had ANCA-positive LN, all of which were MPO-ANCA. There was a positive correlation between MPO-ANCA and SLEDAI, as well as with class IV LN. Receiver operating characteristic analyses revealed that the sensitivity and specificity of MPO-ANCA were 81.3% and 99.8%, respectively, in discriminating LN from systemic lupus without nephritis. Conclusion:: MPO-ANCA level was significantly correlated with SLEDAI, inflammatory markers, kidney function tests, and LN class IV.

Download Full-text

Serum granzyme B is associated with otorhinolaryngological, pulmonary, and renal involvement of antineutrophil cytoplasmic antibody-associated vasculitis

Journal of Investigative Medicine ◽

10.1136/jim-2020-001365 ◽

2020 ◽

Vol 69 (1) ◽

pp. 91-95

Author(s):

Taejun Yoon ◽

Juyoung Yoo ◽

Sung Soo Ahn ◽

Jason Jungsik Song ◽

Yong-Beom Park ◽

...

Keyword(s):

Granzyme B ◽

Renal Involvement ◽

Laboratory Data ◽

Antineutrophil Cytoplasmic Antibody ◽

Immunosuppressive Drug ◽

Cross Sectional ◽

Organ Specific ◽

Drug Naïve ◽

The Cross ◽

Inflammatory Burden

We investigated whether serum granzyme B (GrB) can reflect the inflammatory burden such as cross-sectional disease activity and organ-specific involvement in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Seventy-eight immunosuppressive drug-naïve patients with AAV were included in this study. At the time of the first classification, whole blood was obtained from each patient and sera was immediately isolated and stored at – 80℃. On the day of the blood sampling, we performed routine laboratory tests including antineutrophil cytoplasmic antibody tests and collected both clinical and laboratory data. AAV-specific indices included Birmingham Vasculitis Activity Score (BVAS) and Five-Factor Score (FFS). The median age of patients with AAV was 62 years and 26 patients were men. Serum GrB was not associated with the cross-sectional BVAS; however, patients with serum GrB positivity exhibited higher frequencies of otorhinolaryngological manifestation than those without (p=0.037). When serum GrB levels were compared after dividing the patients into two groups based on the presence of organ-specific involvement, patients with pulmonary involvement exhibited a significantly higher serum GrB than those without (p=0.042). On the other hand, patients with renal involvement showed a significantly lower serum GrB than those without (p=0.023). In addition, serum GrB was inversely correlated with the cross-sectional FFS (r=−0.249, p=0.028). Even though serum GrB could not reflect the inflammatory burden of AAV, serum GrB was associated with otorhinolaryngological, pulmonary, and renal involvement in immunosuppressive drug-naïve patients with AAV.

Download Full-text

Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity

Mediators of Inflammation ◽

10.1155/2020/6243019 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Linrong He ◽

Xiaoming Shu ◽

Xia Liu ◽

Yongpeng Ge ◽

Sizhao Li ◽

...

Keyword(s):

Disease Activity ◽

Clinical Features ◽

Lupus Erythematosus ◽

Laboratory Data ◽

Skin Lesions ◽

Cross Sectional ◽

Cell Counts ◽

Skin Ulcers ◽

Significant Difference ◽

Treatment Naïve

Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), and 20 healthy controls (HCs) by chemiluminescent immunometric assay. Clinical features and laboratory data were collected from electronic medical record. Disease activity was evaluated by using physician global disease activity and myositis disease activity assessment visual analog scale (MYOACT) on admission. 20 DM patients were followed. Serum sIL-2R levels were analyzed and compared with clinical features, laboratory data, and measures of disease activity. Results. Serum sIL-2R levels were significantly higher in DM patients than in IMNM patients and HCs (648.8±433.1 U/ml vs. 352.3±126.0 U/ml and 648.8±433.1 U/ml vs. 285.8±101.9 U/ml, respectively; all P<0.001), while there was no significant difference between IMNM and HCs. There were also no significant differences of sIL-2R levels in DM, SLE, and RA. Importantly, serum sIL-2R levels were significantly higher in treatment-naïve or active DM patients than those that are not (1100.9±550.4 U/ml vs. 615.6±330.4 U/ml, P=0.006; 808.8±421.6 U/ml vs. 339.8±103.4 U/ml, P<0.001). DM patients with skin ulcers had significantly higher sIL-2R levels than those without (889.3±509.9 U/ml vs. 640.0±368.7 U/ml, P=0.023). Cross-sectional analysis in DM showed that sIL-2R levels positively correlated with CK, ESR, CRP, ferritin, physician VAS, and MYOACT scores (rho=0.278, rho=0.474, rho=0.469, rho=0.454, r=0.646, and r=0.600, respectively; all P<0.05), negatively correlated with T cell counts and MMT8 scores (r=−0.380, P=0.002; rho=−0.394, P=0.001). Follow-up study showed that changes in sIL-2R levels after treatment correlated with changes in physician VAS and MYOACT scores (r=0.823 and r=0.695, respectively; all P<0.01). Conclusion. Serum sIL-2R levels were elevated in DM but not in IMNM. Serum sIL-2R could act as a disease activity marker and be associated with ulcerative skin lesions in DM.

Download Full-text

AB0508 PHYSICAL ACTIVITY IN TUNISIAN ADULTS WITH ANKYLOSING SPONDYLITIS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.3187 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1281.2-1281

Author(s):

A. Feki ◽

I. Sellami ◽

R. Akrout ◽

S. Ben Jemaa ◽

Z. Gassara ◽

...

Keyword(s):

Physical Activity ◽

Disease Activity ◽

Activity Index ◽

Short Form ◽

Laboratory Data ◽

Disease Activity Index ◽

P Value ◽

Cross Sectional ◽

Metabolic Equivalent Of Task ◽

High Level

Background:Physical activity (PA) is associated with multiple health-related benefits among the general population and adults with chronic diseases like Ankylosing spondylitis (AS) [1]. As known, AS affects primarily enthesis and can lead to loss of function and decreased mobility.Objectives:The aim of this study was to explore the PA levels of adults with AS and to examine associations between PA, sociodemographic characteristics, immunological features, disease activity and treatment type.Methods:Cross-sectional clinical and laboratory data were collected on 68 AS patients. BASDAI (Bath ankylosing spondylarthritis disease activity index) and BASFI (Bath ankylosing spondylarthritis functional index) were calculated. Physical activity was measured using IPAQ-SF (International Physical Activity Questionnaire-Short Form). Its items record the time spent on physical activity of three intensity levels (vigorous, moderate and walking) as well as the time spent on sitting (referred to as sedentary in this study) in the past week. Both continuous (expressed as metabolic equivalent of task (MET)-min /week) and categorical (3 levels proposed: low, moderate and high level of PA) scores of IPAQ-SF were determined. Sedentary time (median) was reported in minutes/week. A p value < 0.05 was considered significant.Results:Cross-sectional clinical and laboratory data were collected on 68 AS patients. BASDAI (Bath ankylosing spondylarthritis disease activity index) and BASFI (Bath ankylosing spondylarthritis functional index) were calculated. Physical activity was measured using IPAQ-SF (International Physical Activity Questionnaire-Short Form). Its items record the time spent on physical activity of three intensity levels (vigorous, moderate and walking) as well as the time spent on sitting (referred to as sedentary in this study) in the past week. Both continuous (expressed as metabolic equivalent of task (MET)-min /week) and categorical (3 levels proposed: low, moderate and high level of PA) scores of IPAQ-SF were determined. Sedentary time (median) was reported in minutes/week. A p value < 0.05 was considered significant.Conclusion:Our study proved that physical activity in people with AS decreased with age and activity disease with a concomitant increase in sedentary activity. Given the risks of developing secondary chronic disease as a result of low levels of physical activity, physical exercise should be recommended as part of comprehensive AS care.References:[1]Conigliaro P, Triggianese P, Ippolito F, Lucchetti R, Chimenti MS, Perricone R. Insights on the Role of Physical Activity in Patients with Rheumatoid Arthritis. Drug Dev Res. 2014;75:S54–6.Disclosure of Interests:None declared.

Download Full-text

Correlation of Serum Anti-Clq Antibody Levels and Disease Activity in Patients with Systemic Lupus Erythematosus

Indonesian Journal of Rheumatology ◽

10.37275/ijr.v11i1.116 ◽

2019 ◽

Vol 11 (1) ◽

Author(s):

Ferdy Ferdian ◽

Riardi Pramudiyo ◽

Laniyati Hamijoyo

Keyword(s):

Systemic Lupus Erythematosus ◽

Disease Activity ◽

Lupus Erythematosus ◽

High Disease Activity ◽

Systemic Lupus ◽

Cross Sectional ◽

Cross Sectional Design ◽

Complement C1q ◽

Antibody Levels ◽

Self Antigen

Background. Antibody to complement C1q (Anti-C1q Antibody) can be found in Systemic Lupus Erythematosus (SLE) patients. Complement C1q plays a role in the clearance of apoptotic cells and immune complexes. Anti-C1q causes complement C1q become inactive so that the clearance decreases, which induces self antigen and inflammatory response. Many tissue inflammation are associated with disease activity and lupus manifestations. The aim of this study is to find out the correlation of anti-C1q level with disease activity, so that anti-C1q can be used as an objective indicator of inflammation along with SELENA-SLEDAI. Method. This is an analytic descriptive study with cross sectional design. Anti-C1q antibody levels were measured in 52 SLE patients who are hospitalized or treated routinely in outpatient clinic of Rheumatology Dr.Hasan Sadikin Hospital Bandung Indonesia from October to December 2015. Result. Most of the study subjects were women (94%), with a median age of 33 years. There were 13 new patients (25%), and the rest 42 patients were treated routinely. The median SELENA-SLEDAI was 6 (0-32). Subject were divided into no activity (11.5%), low disease activity (34.6%), medium disease activity (25%) high disease activity (15.4%) and very high disease activity (13.5%). Median anti-C1q level was 3.92 U/mL (range 0.6-100.2 U/mL). Anti-C1q antibody levels were positively correlated with SLE disease activity based on SELENA-SLEDAI scores (r=+0.304; p=0.014) Conclusion. Anti-C1q antibody levels has mild correlated with lupus disease activity based on SELENA-SLEDAI score Keywords : Anti-C1q antibody, SLE, SELENA-SLEDAI.

Download Full-text